Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.

Condition:   Interstitial Lymphocytic Lung Disease Interventions:   Drug: Rituximab;   Drug: Abatacept Sponsor:   Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials